Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1684849

	registered interest
	date	24/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dentistry: Higher Education
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of students studying dentistry in universities in England and Wales in the 2023-24 academic year.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	11247
	answer	answer is ministerial correction date of answer 01/02/2024 answer text <p>The Office for Students (OfS) collects and publishes data on the intakes to dentistry degrees in England and Wales. Initial figures from the OfS suggest that, in the 2023/24 academic year, 805 students began dentistry degrees in England, and 70 students began dentistry degrees in Wales. The Department does not hold further information on the overall number of students studying dentistry at universities in England and Wales in the 2023/24 academic year.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 01/02/2024 16:46:01 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	318 label Biography information for John Spellar

1658417

	registered interest
	date	05/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Department of Health and Social Care: Buildings
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department made of the potential prevalence of RAAC in buildings (a) owned and (b) occupied by (i) NHS and (ii) other departmental staff.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	197657
	answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 10:04:33 answering member 4423 label Biography information for Will Quince previous answer version 93682 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
	tabling member	318 label Biography information for John Spellar

1655803

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination: Manufacturing Industries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to A review of the Vaccine Taskforce, published by his Department on 29 August 2023, what additional vaccine production capacity, of any type, has been secured as a result of the investments made (a) by the Vaccine Taskforce and (b) subsequently by the Office for Life Sciences, as described in the report.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	195638
	answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:12:09 answering member 4492 label Biography information for Maria Caulfield
	tabling member	318 label Biography information for John Spellar

1655804

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination: Manufacturing Industries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s paper A review of the Vaccine Taskforce, published on 29 August 2023, what funds the Office for Life Sciences has to invest in additional vaccine production capacity in the UK in order to achieve the onshoring programme objective set for the Vaccines Taskforce.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	195639
	answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:13:16 answering member 4492 label Biography information for Maria Caulfield
	tabling member	318 label Biography information for John Spellar

1625243

	registered interest
	date	02/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the HPV vaccination rate.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	183309
	answer	answer is ministerial correction date of answer 09/05/2023 answer text <p>The human papillomavirus (HPV) vaccination programme is delivered in different locations to maximise access and make getting vaccinated easier. This includes school-based delivery, with alternative sites set up for those not in mainstream education, or for those who missed their initial offer. HPV vaccinations are also offered to men who have sex with men aged up to and including 45-year-olds, through Specialist Sexual Health Services and/or HIV clinics. General practices (GPs) also offer HPV catch-up vaccinations for anyone eligible, until their 25th birthday.</p><p>Additionally, the Department, NHS England and the UK Health Security Agency deliver communication campaigns across GPs and universities to encourage people to get vaccinated. It is vitally important that everyone takes up the vaccinations to which they are entitled, for themselves, their families and wider society. Anyone unsure about their eligibility or vaccination status should contact their GP for advice.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 09/05/2023 12:50:21 answering member 4492 label Biography information for Maria Caulfield
	tabling member	318 label Biography information for John Spellar

1612780

	registered interest
	date	20/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of trends in the numbers of patients participating in clinical trials; and what steps his Department plans to take to increase participation amongst diverse patient groups.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	181874
	answer	answer is ministerial correction date of answer 03/05/2023 answer text <p>Recruitment of new participants into studies is an important measure of research activity taking place in the United Kingdom. This financial year, on average over 70,000 people are recruited per month.</p><p>The National Institute for Health and Care Research (NIHR) has published a strategy to promote diversity and inclusion in research and clinical trials. The NIHR also published its first randomised controlled trials data report, showing that trial participant diversity is consistent with the 2011 census population.</p><p>The Government has appointed Lord James O’Shaughnessy to conduct an independent review into the UK commercial clinical trials landscape. His review will help us to find new ways to conduct commercial clinical trials that will speed up diagnosis, enhance treatment and enable the National Health Service to deliver world-class care.</p> answering member constituency Colchester answering member printed Will Quince question first answered 03/05/2023 10:43:58 answering member 4423 label Biography information for Will Quince
	tabling member	318 label Biography information for John Spellar

1612781

	registered interest
	date	20/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicines and Healthcare products Regulatory Agency: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of (a) staffing and (b) funding for the Medicines and Healthcare products Regulatory Agency in the context of the agency’s new responsibilities under the Windsor Framework.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	181875
	answer	answer is ministerial correction date of answer 27/04/2023 answer text <p>As part of the Spring Budget, the Medicines and Healthcare products Regulatory Agency (MHRA) will receive £10 million of additional funding for the next two years. This is to support it to accelerate routes for bringing innovative medical products developed in the United Kingdom onto the market, as well as to support the establishment of an international recognition framework, allowing the MHRA to capitalise on the expertise and decision making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p> answering member constituency Colchester answering member printed Will Quince question first answered 27/04/2023 11:36:22 answering member 4423 label Biography information for Will Quince
	tabling member	318 label Biography information for John Spellar

1612782

	registered interest
	date	20/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicines and Healthcare products Regulatory Agency: Recruitment and Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will undertake an audit of skills capacity within the Medicines and Healthcare products Regulatory Agency; and what steps he is taking to ensure that any skills needs are met through appropriate (a) recruitment and (b) training.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	181876
	answer	answer is ministerial correction date of answer 26/04/2023 answer text <p>The Department has no plans to undertake an audit of skills within the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA leads responsibility for the recruitment and training of its staff. We receive regular updates on the performance and capacity of the MHRA through established mechanisms, including quarterly and annual accountability reviews.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/04/2023 16:41:02 answering member 4423 label Biography information for Will Quince
	tabling member	318 label Biography information for John Spellar

1612783

	registered interest
	date	20/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicines and Healthcare products Regulatory Agency: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of staffing levels at the Medicines and Healthcare products Regulatory Agency on (a) the time taken by the agency to conduct clinical studies and (b) patient access to clinical studies in each of the last three years.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	181877
	answer	answer is ministerial correction date of answer 26/04/2023 answer text <p>The average response time for the Medicines and Healthcare products Regulatory Agency (MHRA) to issue its initial written opinion following assessment of a clinical trial authorisation application in each of the last three years was 22.83 days for the financial year 2020/21; 27.45 days for the financial year 2021/22; and 45.94 days for the financial year 2022/23.</p><p>The extended timeline for financial year 2022/23 is the result of increased demand to process applications and respond to queries, in response to which the MHRA is increasing resources and improving processes in this area. Vacancies within the Clinical Trials Unit of the MHRA have been filled, including key leadership posts. The MHRA has also recruited seven new clinical trials assessors over the last 12 months and is currently prioritising their training. Moreover, the MHRA is supplementing new assessor capacity with an additional fixed-term resource of appropriately experienced and qualified specialists to support the training and supervision of new staff. The MHRA does not monitor patient access to clinical trials.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/04/2023 16:35:43 answering member 4423 label Biography information for Will Quince
	tabling member	318 label Biography information for John Spellar

1604014

	registered interest
	date	14/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 March 2023 on Question 158778, for what reason the service specification for the school aged flu immunisation programme is not published; and if he will consider the potential merits of publishing this information.
	tabling member constituency	Warley
	tabling member printed	John Spellar
	uin	165198
	answer	answer is ministerial correction date of answer 21/03/2023 answer text <p>The School Aged Immunisation Service (SAIS) specification covers all school age immunisations, including flu. It is a template for NHS England regional commissioners to commission SAIS providers that evolves in line with latest policy advice, for example, the addition of flu cohorts. Contracts are held between NHS England regions and SAIS providers and are varied to best meet local need. It is on these grounds NHS England does not publish the specification. This is in contrast to the general practitioner and community pharmacy flu service specifications, which are published as they are part of a national contract. However, each year the annual flu letter is published by the UK Health Security Agency and outlines which groups are eligible for a free vaccine as part of the National Health Service programme, including children.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 21/03/2023 15:21:23 answering member 4492 label Biography information for Maria Caulfield
	tabling member	318 label Biography information for John Spellar